Vaccinex Sees Mixed Signals In Huntington’s Study
Pepinemab Missed Key Endpoints In Phase II Trial
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
You may also be interested in...
The summer slowdown finally seems to have hit the US biopharma IPO market; after a hot July with nine offerings, there were just two during the first half of August. Also, Zogenix leads recent follow-ons with a $312m offering; venture capital planted in UK biotechs – Orchard and Blueberry.
Laquinimod fails to impress in a Phase II study in Huntington's disease, adding to a series of clinical trial setbacks over past years for the potential oral immunomodulator.
Impending clinical trial readouts will indicate whether pharmaceutical companies are on the right track to develop new investigational agents against the cause of the neurodegenerative disorder, Huntington's disease.